- Home
- ADTX
ADTX
Aditxt Inc.
as 04-25-2025 4:00pm EST
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | RICHMOND |
| Market Cap: | 5.3M | IPO Year: | 2020 |
| Target Price: | N/A | AVG Volume (30 days): | 589.6K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3062.42 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.04 - $27200.00 | Next Earning Date: | 05-19-2025 |
| Revenue: | $133,985 | Revenue Growth: | -79.23% |
| Revenue Growth (this year): | 15768.94% | Revenue Growth (next year): | N/A |
Latest Aditxt Inc. News
ADTX Breaking Stock News: Dive into ADTX Ticker-Specific Updates for Smart Investing
Business Wire
9 days ago
Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimune™
Business Wire
10 days ago
Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025
Business Wire
12 days ago
Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials
Business Wire
15 days ago
Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements
Insider Monkey
16 days ago
Why Aditxt Inc. (ADTX) Went Down On Thursday?
Business Wire
17 days ago
Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements
GlobeNewswire
24 days ago
Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025
Business Wire
24 days ago
Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025
Compare ADTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADTX Aditxt Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.